<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03921021</url>
  </required_header>
  <id_info>
    <org_study_id>1807019403</org_study_id>
    <nct_id>NCT03921021</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma</brief_title>
  <official_title>Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oncolys BioPharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study of OBP-301 with pembrolizumab in advanced gastric and
      gastroesophageal junction adenocarcinoma that has progressed on at least 2 lines of prior
      therapy for advanced disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II study of OBP-301 with pembrolizumab in advanced gastric and
      gastroesophageal junction adenocarcinoma that has progressed on at least 2 lines of prior
      therapy for advanced disease. Pembrolizumab has recently received FDA approval for PD-L1
      positive gastric and GEJ adenocarcinoma based on the Keynote-059 study. The efficacy of
      pembrolizumab monotherapy is modest in PD-L1 positive patients (defined as a combined
      positive score, CPS, of &gt; 1), with only a ~15% overall response rate. This study will examine
      the addition of the oncolytic virus, OBP-301, administered prior to pembrolizumab in this
      patient population. Patients will be enrolled in a two-stage design, with 18 patients in the
      first stage. All patients will receive OBP-301 at 1x1012 viral particles (VP)/ tumor
      injection administered every two weeks x 4 injections as well as standard dose pembrolizumab
      200 mg IV every 3 weeks. The tumor will be injected with OBP-301 four times (d1, d15, d29,
      d43). The preference is to inject the primary tumor endoscopically. Metastatic lesions may be
      injected on a case-by-case basis after discussion with the PI (Shah). All patients treated
      with OBP-301 will be eligible for the safety cohort. 41 subjects will be recruited in total
      for both stage 1 and 2, to achieve 37 evaluable patients.

      The primary endpoint is to examine the efficacy of OBP-301 with pembrolizumab in PD-L1
      positive advanced gastric and gastroesophageal junction adenocarcinoma in the 3rd or 4th line
      setting, as assessed by the RECIST response rate and to to examine the safety of multiple
      OBP-301 intratumoral injections in combination with pembrolizumab in advanced
      gastroesophageal adenocarcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2019</start_date>
  <completion_date type="Anticipated">March 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate, as assessed by radiographic imaging</measure>
    <time_frame>2 year</time_frame>
    <description>Examination of patients with a partial response or complete response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate, as assessed by radiographic imaging</measure>
    <time_frame>1 year</time_frame>
    <description>Examination of subjects with stable disease, a partial response, or complete response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response, as assessed by radiographic imaging</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the duration that subjects who have responded to combination therapy remain without disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival, as assessed by survival</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the time from registration to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival, as assessed by radiographic imaging and survival.</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the time from registration to cancer progression or death due to any cause</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in tumor-immune microenvironment, as measured by bulk RNA sequencing and single-cell RNA sequencing.</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>In this aim we will summarize the results from all patient data to assess what are the consistent changes observed in cellular composition in response to immunotherapy and we will investigate how these changes impact response to treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in T-cell response, as measured by TCR-sequencing of tumor biopsies</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>This project will be focused on analyzing the immune landscape of individual tumors from tumor biopsies taken at baseline and on therapy. We will analyze changes associated with relapse and differences between refractory and sensitive patients. Our proposed analysis will take as input somatic mutations, raw WES reads, and raw RNA-Seq reads</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Immune Infiltrate by multi-parameter flow-cytometry</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>This powerful approach will be utilized to characterize tumor immune cell infiltrates at baseline, following the induction of combination therapy and at the time of resection. This will be one of the first longitudinal analyses of tumor immune cell infiltrates by multi-parameter flow cytometry following immunotherapy.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Esophagogastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Telomelysin (OBP-301)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive Telomelysin (OBP-301) at 1x1012 viral particles (VP)/ tumor injection administered every two weeks x 4 injections as well as standard dose pembrolizumab 200 mg IV every 3 weeks. The tumor will be injected with OBP-301 four times (d1, d15, d29, d43). The preference is to inject the primary tumor endoscopically. Metastatic lesions may be injected on a case-by-case basis after discussion with the PI (Shah).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telomelysin</intervention_name>
    <description>OBP-301, the investigational product (IP) is formulated in 20 mM Tris pH 8.0, 25 mM NaCl with 2.5% glycerin, USP by volume. OBP-301 will be injected into the target tumor lesions.</description>
    <arm_group_label>Telomelysin (OBP-301)</arm_group_label>
    <other_name>OBP-301</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be willing and able to provide written informed consent for the trial.

          -  Be &gt;18 years of age on the day of signing the informed consent.

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Have histologically or cytologically confirmed advanced or metastatic gastric or
             gastroesophageal junction adenocarcinoma.

          -  Tumor should be at least 1 cm in size and amenable to intratumoral injection.

          -  Patient must have received at least 2 lines of systemic therapy for advanced disease.

          -  Tumor must be PD-L1 positive, as defined by a combined positive score (CPS).

          -  Have one or more measurable lesions based on iRECIST.

          -  Be willing to provide tissue; newly obtained endoscopic biopsy specimens or
             formalin-fixed, paraffin-embedded (FFPE) block specimens.

          -  Female subjects of childbearing potential have a negative urine or serum pregnancy
             test within 7 days prior to enrollment. If the urine test is positive or cannot be
             confirmed as negative, a serum pregnancy test will be required. It is allowed that the
             test at the same day at 7 days prior to enrollment. And male / female subjects of
             childbearing potential must agree to use an adequate method of contraception starting
             with signing the informed consent through 120 days after the last dose of study
             medication.

          -  Demonstrated adequate organ function as defined in following criteria. All screening
             labs should be performed within 14 days of enrollment. Note: Subject must not have
             taken transfusion, hematopoietic agent; granulocyte-colony stimulating factor (G-CSF)
             etc., and/or oxygen supplementation within 7 days before the screening labs.

        Absolute neutrophil count (ANC)&gt;=1,000 /mm3 Platelets&gt;=100,000 /mm3 Hemoglobin&gt;=9.0 g/dL
        Serum total bilirubin&lt;=2.0 mg/dL Aspartate aminotransferase (AST) (SGOT) and alanine
        aminotransferase (ALT) (SGPT)&lt;= 2.5x Upper limit of normal (ULN). For subjects with liver
        metastases&lt;= 5x ULN.

        Serum creatinine&lt;= 1.5 mg/dL; or if serum creatinine &gt; 1.5 mg/dL, measured or c calculated
        creatinine/clearance &gt;=60 mL/min (Cockcroft-Gault formula).

          -  Life expectancy of â‰¥ 6 months from the first OBP-301 treatment.

          -  Understand the study requirements and the treatment procedures, and is willing to
             comply with all specified follow-up evaluations, and provides written informed consent
             before any study-specific tests or procedures are performed.

        Exclusion Criteria:

          -  The presence of any of the following criteria will constitute cause for the exclusion
             of the participant:1. Is currently participating and receiving study therapy or has
             participated in a study of an investigational agent and received study therapy within
             4 weeks of study Day 1.

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years.

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (greater
             than equivalent of prednisone 20 mg/day) or any other form of immunosuppressive
             therapy within 7 days prior to study Day 1.

          -  Has known active central nervous system metastases and/or carcinomatous meningitis.

          -  Has had prior anti-cancer monoclonal antibody chemotherapy, targeted small molecule
             therapy, or radiation therapy within 2 weeks prior to study Day 1, who has not
             recovered from adverse events due to a previously administered agent.

          -  Has had prior immunotherapy targeted to Programmed cell death 1 (PD-1), PD-L1 or
             PD-L2.

          -  Has a known additional malignancy within 3 years of first injection of OBP-301 that is
             progressing or requires active treatment, with the exception of prostate cancer
             controlled with androgen deprivation therapy.

          -  Has received a live vaccine within 30 days of planned start of study therapy.

          -  Patients known to have acute or chronic active hepatitis B virus (HBV), hepatitis C
             virus (HCV), or human immunodeficiency virus (HIV).

          -  Has known history of, or any evidence of active, non-infectious pneumonitis.

          -  Has an active infection requiring systemic therapy within 2 weeks of Day 1.

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the screening visit through 120 days
             after the last dose of trial treatment.

          -  Previous severe hypersensitivity to another monoclonal antibody

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.

          -  Uncontrolled intercurrent illness including, but not limited to, uncontrolled
             diabetes, ongoing or active infection, symptomatic congestive heart failure, unstable
             angina pectoris, cardiac arrhythmia, or psychiatric illness/psychological
             incompetence, whereby in the opinion of the Investigator the patient is assessed as
             being unable to provide information, consent, or comply with the study requirements
             and procedures.

          -  Patients who are pregnant or breastfeeding, or expecting to conceive or father
             children within the projected timeframe of the study, starting from the time of the
             Screening Visit through 4 months (120 days) after the last OBP-301 administration.
             Females of childbearing potential must have a negative serum or urine pregnancy test
             at Screening. A female not of childbearing potential is one who has undergone
             bilateral oophorectomy or who has had no menses for 12 consecutive months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manish Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabrina Machado, RN</last_name>
    <phone>646.962.3378</phone>
    <email>sam4006@med.cornell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manish Shah, MD</last_name>
      <phone>646-962-6200</phone>
      <email>mas9313@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeta Popa, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Allyson Ocean, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Ruggiero, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Doru Paul, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2019</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

